Royalty Pharma, Cytokinetics Expand Funding Up to $575 M for Commercial Launch, R&D

 

• Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise

 Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed specialty cardiology business.

https://www.globenewswire.com/news-release/2024/05/22/2886859/0/en/Royalty-Pharma-and-Cytokinetics-Announce-Expanded-Strategic-Funding-Collaboration-Totaling-Up-to-575-Million-to-Support-Commercial-Launch-of-Aficamten-and-to-Advance-R-D-Pipeline.html